Publication: Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.
Loading...
Identifiers
Date
2020-06-17
Authors
Dominguez-Mozo, Maria Inmaculada
Perez-Perez, Silvia
Villar, Luisa Maria
Oliver-Martos, Begoña
Villarrubia, Noelia
Matesanz, Fuencisla
Costa-Frossard, Lucienne
Pinto-Medel, Maria Jesus
Garcia-Sanchez, Maria Isabel
Ortega-Madueño, Isabel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group
Abstract
There are an increasing number of treatments available for multiple sclerosis (MS). The early identification of optimal responders to individual treatments is important to achieve individualized therapy. With this aim, we performed a multicenter retrospective longitudinal study including 186 MS patients treated with natalizumab who were followed for 2 years. We analyzed the following variables at recruitment: sex, current age, age at disease onset, disease duration, EDSS, number of T2 and Gd + lesions, IgG and IgM oligoclonal bands, HLA class II (DR, DRB, DQA, DQB, and DRB1*15:01), IgG and IgM antibody titers against human herpesvirus 6 (HHV-6) and the antibody response to Epstein-Barr virus (EBV) through the measurement of the anti-EBNA-1 and anti-VCA IgG titers, in relation to clinical response (no relapses or disability progression), and to NEDA-3 (no evidence of disease activity in terms of clinical response and no changes in MRI scans either) after 2-years follow-up. Baseline EDSS score, baseline EBNA-1 IgG titers and percentage change of HHV6 IgG titers between baseline and 6 month visits were significantly different in clinical responders and in NEDA-3 status (all of them remained significant in the multivariate analysis). We identified three variables for the early identification of natalizumab optimal responders in a rapid and cost-effective approach.
Description
MeSH Terms
Adult
Antibody Formation
Biomarkers, Pharmacological
Capsid Proteins
Disease Progression
Epstein-Barr Virus Infections
Epstein-Barr Virus Nuclear Antigens
Female
HLA Antigens
Herpesvirus 4, Human
Herpesvirus 6, Human
Humans
Immunoglobulin G
Longitudinal Studies
Male
Middle Aged
Multiple Sclerosis
Natalizumab
Prognosis
Recurrence
Retrospective Studies
Spain
Antibody Formation
Biomarkers, Pharmacological
Capsid Proteins
Disease Progression
Epstein-Barr Virus Infections
Epstein-Barr Virus Nuclear Antigens
Female
HLA Antigens
Herpesvirus 4, Human
Herpesvirus 6, Human
Humans
Immunoglobulin G
Longitudinal Studies
Male
Middle Aged
Multiple Sclerosis
Natalizumab
Prognosis
Recurrence
Retrospective Studies
Spain
DeCS Terms
Antibody Formation
Biomarkers, Pharmacological
Capsid Proteins
Disease Progression
Epstein-Barr Virus Infections
Epstein-Barr Virus Nuclear Antigens
Female
Biomarkers, Pharmacological
Capsid Proteins
Disease Progression
Epstein-Barr Virus Infections
Epstein-Barr Virus Nuclear Antigens
Female
CIE Terms
Keywords
Adult, Antibody Formation, Biomarkers, Pharmacological, Capsid Proteins, Disease Progression
Citation
Dominguez-Mozo MI, Perez-Perez S, Villar LM, Oliver-Martos B, Villarrubia N, Matesanz F, Costa-Frossard L, Pinto-Medel MJ, García-Sánchez MI, Ortega-Madueño I, et al. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. Sci Rep. 2020 Aug 28;10(1):14244